Please login or register first to view this content.
Psychiatric Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Drug Therapy for Borderline Personality Disorder Evaluated
Viloxazine Under Review for ADHD Treatment in Adults
Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia
Application for Long-Acting Schizophrenia Treatment Accepted for Review
Opioid Tapering Tied to Higher Risk for Overdose, Mental Health Crisis
Transcranial Magnetic Stimulation Device Cleared for Anxious Depression
Lyme Disease Tied to Higher Risk for Psychiatric Conditions, Suicide
Almost Half of Pediatric Opioid Prescriptions Considered High-Risk
Only 1 State Asks All Recommended Physician Mental Health Questions on Licensing Applications
Xywav Approved for Idiopathic Hypersomnia
Study Shows Loneliness Tied to Use of High-Risk Medications
Important Clozapine REMS Program Changes Announced
Oral Orexin Agonist Gets Breakthrough Therapy Status for Narcolepsy Type 1
Relapse Risk for Psychosis in Dementia Lower With Continued Pimavanserin
Prescription Digital Therapeutic for Anxiety, Depression Treatment Launched
Azstarys, a Novel ADHD Treatment, Now Available
Alcohol Withdrawal: Individualized Care and Pharmacologic Treatment
Short-Course Zuranolone Looks Promising for MDD Treatment
